The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

Cited by (1,000)

Items 101–200 of 1,000

1. Processing Speed is Impaired in Adults with Autism Spectrum Disorder, and Relates to Social Communication Abilities
   Sarah M. Haigh, Jennifer A. Walsh, Carla A. Mazefsky, Nancy J. Minshew, Shaun M. Eack · 2018 · Journal of Autism and Developmental Disorders
2. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders
   Alan F. Breier, Emily Liffick, Tom A. Hummer, Jenifer L. Vohs, Ziyi Yang, Nicole F. Mehdiyoun, Andrew C. Visco, Emmalee Metzler, Ying Zhang, Michael Francis · 2018 · Schizophrenia Research
3. The neurophenomenology of early psychosis: An integrative empirical study
   Barnaby Nelson, Suzie Lavoie, Łukasz Gawęda, E. Li, Louis Arnorsson Sass, Danny Koren, Patrick D. McGorry, Bradley N. Jack, Josef Parnas, Andrea R. Polari et al. · 2019 · Consciousness and Cognition
4. Cognitive burden of anticholinergic medications in psychotic disorders
   Seenae Eum, S. Kristian Hill, Leah H. Rubin, Ryan M. Carnahan, James L. Reilly, Elena I. Ivleva, Sarah Keedy, Carol A. Tamminga, Godfrey D. Pearlson, Brett A. Clementz et al. · 2017 · Schizophrenia Research
5. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
   Antonio Vita, Wolfgang Gäebel, Armida Mucci, Gabriele Sachs, Andreas Erfurth, Stefano Barlati, Federico Zanca, Giulia Maria Giordano, Louise Birkedal Glenthøj, Merete Nordentoft et al. · 2022 · European Psychiatry
6. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry
   Leslie G. Nucifora, T Tanaka, Lindsay N. Hayes, M. Kim, Brian J. Lee, T Matsuda, Frederick Charles Nucifora, Thomas W. Sedlak, Ramin Mojtabai, William W. Eaton et al. · 2017 · Translational Psychiatry
7. Social cognition and neurocognitive deficits in first-episode schizophrenia
   Vibeke Bliksted, Birgitte Fagerlund, Ethan Weed, Chris Frith, Poul Videbech · 2014 · Schizophrenia Research
8. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
   Akihiro Shiina, Yukihiko Shirayama, Tomihisa Niitsu, Tasuku Hashimoto, Taisuke Yoshida, Tadashi Hasegawa, Tadashi Haraguchi, Nobuhisa Kanahara, Tetsuya Shiraishi, Mihisa Fujisaki et al. · 2010 · Annals of General Psychiatry
9. Predictors of subjective and objective quality of life in outpatients with schizophrenia
   Ken Yamauchi, Hirofumi Aki, Masahito Tomotake, Jun‐ichi Iga, Syusuke Numata, Ikuyo Motoki, Yumiko Izaki, Shin’Ya Tayoshi, Sawako Kinouchi, Satsuki Sumitani et al. · 2008 · Psychiatry and Clinical Neurosciences
10. Alterations in hippocampal connectivity across the psychosis dimension
    Niyatee P. Samudra, Elena I. Ivleva, Nicholas A. Hubbard, Bart Rypma A, John A. Sweeney, Brett A. Clementz, Matcheri S. Keshavan, Godfrey D. Pearlson, Carol A. Tamminga · 2015 · Psychiatry Research Neuroimaging
11. Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation
    Roberto Cavallaro, Simona Anselmetti, Sara Poletti, Margherita Bechi, Elena Ermoli, Federica Cocchi, Paolo Stratta, Antonio Vita, Alessandro Rossi, Enrico Smeraldi · 2009 · Psychiatry Research
12. Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study
    Anthony Charles Ruocco, James L. Reilly, Leah H. Rubin, Alex R. Daros, Elliot S. Gershon, Carol A. Tamminga, Godfrey D. Pearlson, S. Kristian Hill, Matcheri S. Keshavan, Ruben C. Gur et al. · 2014 · Schizophrenia Research
13. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
    T. Scott Stroup, Paul S. Appelbaum, Marvin S. Swartz, Mukesh Kumar Patel Mukesh Kumar Patel, Sonia Thomas, Dilip V. Jeste, Scott Y. H. Kim, Richard S.E. Keefe, Theo C. Manschreck, Joseph M. McEvoy et al. · 2005 · Schizophrenia Research
14. Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study
    Cohen, Asher, Naslund, John A., Chang, Sarah, Nagendra, Srilakshmi, Bhan, Anant, Rozatkar, Abhijit, Thirthalli, Jagadisha, Bondre, Ameya, Tugnawat, Deepak, Reddy, Preethi V. et al. · 2023 · Schizophrenia
15. Stress-Induced Increase in Kynurenic Acid as a Potential Biomarker for Patients With Schizophrenia and Distress Intolerance
    Joshua Chiappelli, Ana Pocivavsek, Katie L. Nugent, Francesca M. Notarangelo, Peter Kochunov, Laura M. Rowland, Robert M. Schwarcz, Liyi Elliot Hong · 2014 · JAMA Psychiatry
16. Cognition as an outcome measure in schizophrenia
    Michael Kraus, Richard S.E. Keefe · 2007 · The British Journal of Psychiatry
17. Spanish Validation Of the Brief Assessment in Cognition in Schizophrenia (Bacs) in Patients With Schizophrenia and Healthy Controls
    Núria Segarra, Miquel Bernardo, Fernando Gutiérrez, Azucena Justicia, E. Fernadez-Egea, M. Allas, Gemma Safont, Fernando Contreras, Joaquím Gascón, Pere Antoni Soler Insa et al. · 2010 · European Psychiatry
18. Validation of the tablet-administered Brief Assessment of Cognition (BAC App)
    Alexandra S. Atkins, Tina Tseng, Adam W. Vaughan, Elizabeth W. Twamley, Philip D. Harvey, Thomas L. Patterson, Meera Narasimhan, Richard S.E. Keefe · 2016 · Schizophrenia Research
19. Dietary patterns and physical activity in people with schizophrenia and increased waist circumference
    Ane Storch Jakobsen, Helene Speyer, Hans Christian Brix Nørgaard, Mette Karlsen, Carsten Rygaard Hjorthøj, Jesper Krogh, Ole N Mors, Merete Nordentoft, Ulla Toft · 2018 · Schizophrenia Research
20. Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool
    Janna N. de Boer, Alban Voppel, Sanne Brederoo, Hugo Gerard Schnack, Khiet P. Truong, Frank N. K. Wijnen, Iris E. Sommer · 2021 · Psychological Medicine
21. Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data
    Elisabetta Caletti, Riccardo Augusto Paoli, Alessio Fiorentini, Michela Cigliobianco, Elisa Zugno, Marta Serati, Giulia Orsenigo, Paolo Grillo, Stefano Zago, Alice Caldiroli et al. · 2013 · Frontiers in Human Neuroscience
22. Using Online Screening in the General Population to Detect Participants at Clinical High-Risk for Psychosis
    Mhairi McDonald, Eleni Christoforidou, Nicola J. van Rijsbergen, Ruchika Gajwani, Joachim Groß, Andrew Ian Gumley, Stephen M. Lawrie, Matthias Schwannauer, Frauke Schultze‐Lutter, Peter J. Uhlhaas · 2018 · Schizophrenia Bulletin
23. Functional network connectivity impairments and core cognitive deficits in schizophrenia
    Bhim Mani Adhikari, Liyi Elliot Hong, Hemalatha Sampath, Joshua Chiappelli, Neda Jahanshad, Paul M. Thompson, Laura M. Rowland, Vince D. Calhoun, Xiaoming Michael Du, Shuo Chen et al. · 2019 · Human Brain Mapping
24. Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
    Rafael Ribeiro-Santos, Antônio Lúcio Teixeira, João Vinícius Salgado · 2014 · Current Neuropharmacology
25. Double-blind randomized controlled study showing symptomatic and cognitive superiority of bifrontal over bitemporal electrode placement during electroconvulsive therapy for schizophrenia
    Vivek Haridas Phutane, Jagadisha Thirthalli, Kesavan Muralidharan, Channaveerachari Naveen Kumar, Janakiprasad Keshav Kumar, Bangalore N. Gangadhar · 2012 · Brain stimulation
26. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses
    Andrea de Bartolomeis, Raffaele Balletta, Sara Giordano, Elisabetta Filomena Buonaguro, Gianmarco Latte, Felice Iasevoli · 2013 · Psychiatry Research
27. The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders
    Nikolai Albert, Marianne Melau, Heidi Jensen, Lene Halling Hastrup, Carsten Rygaard Hjorthøj, Merete Nordentoft · 2017 · Schizophrenia
28. Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies
    Soichiro Nakahara, Mitsuyuki Matsumoto, Theo G.M. van Erp · 2018 · Neuropsychopharmacology Reports
29. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
    Igne Sinkeviciute, Marieke Begemann, Merel Prikken, Bob Oranje, Erik Johnsen, Wan U. Lei, Kenneth Hugdahl, Rune A. Kroken, Carina Rau, Jolien D. Jacobs et al. · 2018 · Schizophrenia
30. Tryptophan Metabolism and White Matter Integrity in Schizophrenia
    Joshua Chiappelli, Teodor T. Postolache, Peter Kochunov, Laura M. Rowland, S. Andrea Wijtenburg, Dinesh K Shukla, Malle A. Tagamets, Xiaoming Michael Du, Anya Savransky, Christopher A. Lowry et al. · 2016 · Neuropsychopharmacology
31. Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder
    Nadia Bakkour, Jennifer C. Samp, Kasem S. Akhras, Emna El Hammi, Imen Soussi, Fatma Zahra, Gérard Duru, Amna Kooli, Mondher Toumi · 2014 · Psychiatry Research
32. Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study
    Hidese, Shinsuke, Ota, Miho, Wakabayashi, Chisato, Noda, Takamasa, Ozawa, Hayato, Okubo, Tsutomu, Kunugi, Hiroshi · 2017 · Acta Neuropsychiatrica
33. Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning
    Koichi Kaneko · 2018 · Yonago acta medica
34. 40-Hz Auditory Steady-State Responses Characterize Circuit Dysfunctions and Predict Clinical Outcomes in Clinical High-Risk for Psychosis Participants: A Magnetoencephalography Study
    Tineke Grent-‘t-Jong, Ruchika Gajwani, Joachim Groß, Andrew Ian Gumley, Rajeev Krishnadas, Stephen M. Lawrie, Matthias Schwannauer, Frauke Schultze‐Lutter, Peter J. Uhlhaas · 2021 · Biological Psychiatry
35. The heterogeneity of antipsychotic response in the treatment of schizophrenia
    M. Case, Virginia L. Stauffer, Haya Ascher‐Svanum, Robert R. Conley, Shitij Kapur, John Michael Kane, Sara Kollack‐Walker, Jayanthi Jacob, Bruce J. Kinon · 2010 · Psychological Medicine
36. Working Memory in Schizophrenia: An EEG Study Using Power Spectrum and Coherence Analysis to Estimate Cortical Activation and Network Behavior
    Ellie Pachou, Michael Vourkas, Panagiotis G. Simos, Dirk J. A. Smit, Cornelis Jan Stam, Vasso Tsirka, Sifis Micheloyannis · 2008 · Brain Topography
37. Infection and inflammation in schizophrenia and bipolar disorder
    Teppei Tanaka, Taro Matsuda, Lindsay N. Hayes, Shuojia Yang, Katrina M. Rodriguez, Emily G. Severance, Robert H. Yolken, Akira Sawa, William W. Eaton · 2016 · Neuroscience Research
38. Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study
    Sara Bergh, Carsten Rygaard Hjorthøj, Holger Jelling Sørensen, Birgitte Fagerlund, Stephen F. Austin, Rikke Gry Secher, Jens Richardt M. Jepsen, Merete Nordentoft · 2016 · Schizophrenia Research
39. Prospective memory in Parkinson disease across laboratory and self-reported everyday performance.
    Erin R. Foster, Mark A. McDaniel, Grega Repovš, Tamara G. Hershey · 2009 · Neuropsychology
40. Social cognition in 22q11.2 microdeletion syndrome: Relevance to psychosis?
    Maria Jalbrzikowski, Chelsea Carter, Damla Şentürk, Carolyn C. Chow, Jessica M. Hopkins, Michael Foster Green, Adriana Galván, Tyrone D. Cannon, Carrie E. Bearden · 2012 · Schizophrenia Research
41. Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia
    Zixu Yang, Nur Amirah Abdul Rashid, Yue Feng Quek, Max Lam, Yuen Mei See, Yogeswary Maniam, Justin Dauwels, Bhing‐Leet Tan, Jimmy Lee · 2018 · Schizophrenia Research
42. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder
    Sofie Houthoofd, Manuel Morrens, Bernard Sabbe · 2008 · Clinical Therapeutics
43. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial
    Marieke Begemann, Ilse A. Thompson, Wim Veling, Shiral S. Gangadin, Chris Neeltje Wil Geraets, Erna van’t Hag, Sanne J. Müller-Kuperus, Priscilla P. Oomen, Alban Voppel, Mark van der Gaag et al. · 2020 · Trials
44. Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S)
    Emilio Rojo, Óscar Pino, Georgina Guilera, Juana Gómez‐Benito, Scot E. Purdon, Benedicto Crespo‐Facorro, Manuel Jesús Cuesta, Manuel Franco, Anabel Martínez‐Arán, Núria Segarra et al. · 2009 · Schizophrenia Research
45. A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal Cognitive Assessment (MoCA)
    Caili Wu, Paul Dagg, Carmen Molgat · 2014 · Schizophrenia Research
46. 20‐year trajectories of positive and negative symptoms after the first psychotic episode in patients with schizophrenia spectrum disorder: results from the OPUS study
    Marie Stefanie Kejser Starzer, Helene Gjervig Hansen, Carsten Rygaard Hjorthøj, Nikolai Albert, Merete Nordentoft, Trine Madsen · 2023 · World Psychiatry
47. A brief cognitive assessment for use with schizophrenia patients in community clinics
    Dawn I. Velligan, Margaret DiCocco, C. Christine Bow-Thomas, Christopher Cadle, David C. Glahn, Alexander L. Miller, Melanie M. Biggs, Kathy Shores‐Wilson, Christine A. McKenzie, M. Lynn Crismon · 2004 · Schizophrenia Research
48. Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder
    Christoforos Iraklis Giakoumatos, Pranav Nanda, Ian T. Mathew, Neeraj Tandon, Jai L. Shah, Jeffrey R. Bishop, Brett A. Clementz, Godfrey D. Pearlson, John A. Sweeney, Carol A. Tamminga et al. · 2014 · Journal of Psychiatric Research
49. Cognitive impairment in manic bipolar patients: important, understated, significant aspects
    M. Vrabie, Victor Marinescu, A. Talasman, Oana-Florentina Tautu, Eduard Polea Drima, I. Micluția · 2015 · Annals of General Psychiatry
50. MEASURING COGNITIVE FUNCTION IN MDD: EMERGING ASSESSMENT TOOLS
    Manuela Russo, Katie Mahon, Katherine E. Burdick · 2014 · Depression and Anxiety
51. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls
    Rebecca Shafee, Pranav Nanda, Jaya L. Padmanabhan, Neeraj Tandon, Ney Alliey‐Rodriguez, Sreeja S. Kalapurakkel, Daniel J. Weiner, Raquel E. Gur, Richard S.E. Keefe, Scot Kristian Hill et al. · 2018 · Translational Psychiatry
52. Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk
    Meghan A. Collins, Jie Lisa Ji, Yoonho Chung, Cole A. Lympus, Yvette Afriyie-Agyemang, Jean Addington, Bradley Gordon Goodyear, Carrie E. Bearden, Kristin S. Cadenhead, Heline Mirzakhanian et al. · 2022 · Molecular Psychiatry
53. Theory of mind and emotion processing training for patients with schizophrenia: Preliminary findings
    Margherita Bechi, Roberta Riccaboni, Serena Ali, Francesco Fresi, Mariachiara Buonocore, Marta Bosia, Federica Cocchi, Enrico Smeraldi, Roberto Cavallaro · 2012 · Psychiatry Research
54. Neuroscience-informed auditory training in schizophrenia: A final report of the effects on cognition and serum brain-derived neurotrophic factor
    Melissa Fisher, Synthia H. Mellon, Owen M. Wolkowitz, Sophia Vinogradov · 2015 · Schizophrenia Research Cognition
55. Remote “Hovering” With Individuals With Psychotic Disorders and Substance Use: Feasibility, Engagement, and Therapeutic Alliance With a Text-Messaging Mobile Interventionist
    Dror Ben‐Zeev, Susan M. Kaiser, Izabela M. Krzos · 2014 · Journal of Dual Diagnosis
56. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia
    Seung‐Hwan Lee, Kyongae Sung, Kyong-Sang Lee, Eunok Moon, Chang-Gyu Kim · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
57. Behavioral response inhibition in psychotic disorders: Diagnostic specificity, familiality and relation to generalized cognitive deficit
    Lauren E. Ethridge, Melanie Soilleux, Paul A. Nakonezny, James L. Reilly, S. Kristian Hill, Richard S.E. Keefe, Elliot S. Gershon, Godfrey D. Pearlson, Carol A. Tamminga, Matcheri S. Keshavan et al. · 2014 · Schizophrenia Research
58. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms
    Mihai Avram, Felix Brandl, Jorge Cabello, Claudia Leucht, Martin Scherr, Mona Mustafa, Stefan Leucht, Sibylle Ilse Ziegler, Christian Sorg · 2019 · Brain
59. Whole-Brain Source-Reconstructed MEG-Data Reveal Reduced Long-Range Synchronization in Chronic Schizophrenia
    Jonni Hirvonen, Michael Wibral, Jaakko Matias Palva, Wolf Singer, Peter J. Uhlhaas, Satu Palva · 2017 · eNeuro
60. What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors
    Aaron Tim Beck, Robyn Himelstein, Keith Bredemeier, Steven M. Silverstein, Paul M. Grant · 2018 · Psychological Medicine
61. Cost-effectiveness of cognitive remediation and supported employment for people with mental illness: a randomized controlled trial
    Sosei Yamaguchi, Sayaka Sato, N Horio, Koji Yoshida, Michiyo Shimodaira, Ayano Taneda, Emi Ikebuchi, M. Nishio, Junichiro Ito · 2016 · Psychological Medicine
62. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia
    Puay San Woon, Ming Ying Chia, Wai Yen Chan, Kang Sim · 2010 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
63. NEURAPRO‐E study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders
    Connie Markulev, Patrick D. McGorry, Barnaby Nelson, Hok Pan Yuen, Miriam R. Schaefer, Alison Ruth Yung, Andrew David Thompson, Gregor Emanuel Berger, Nilufar Mossaheb, Monika Schlögelhofer et al. · 2015 · Early Intervention in Psychiatry
64. Sleep endophenotypes of schizophrenia: slow waves and sleep spindles in unaffected first-degree relatives
    Armando D’Agostino, Anna Castelnovo, Simone Cavallotti, Cecilia Casetta, Matteo Marcatili, Orsola Gambini, Mariapaola Canevini, Giulio Tononi, Brady A. Riedner, Fabio Ferrarelli et al. · 2018 · Schizophrenia
65. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial
    Luke K. Bolt, G. Paul Amminger, John Farhall, Patrick D. McGorry, Barnaby Nelson, Connie Markulev, Hok Pan Yuen, Miriam R. Schäfer, Nilufar Mossaheb, Monika Schlögelhofer et al. · 2018 · Schizophrenia Research
66. Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
    Joshua T. Kantrowitz · 2020 · CNS Drugs
67. Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome
    Philip D. Harvey, Richard S.E. Keefe, Thomas L. Patterson, Robert K. Heaton, Christopher R. Bowie · 2008 · Journal of Clinical and Experimental Neuropsychology
68. ‘Theory’ of mind impairment in patients affected by schizophrenia and in their parents
    Simona Anselmetti, Margherita Bechi, Marta Bosia, C. Quarticelli, Elena Ermoli, Enrico Smeraldi, Roberto Cavallaro · 2009 · Schizophrenia Research
69. Association of obesity with cognitive function and brain structure in patients with major depressive disorder
    Hidese, Shinsuke, Ota, Miho, Matsuo, Junko, Ishida, Ikki, Hiraishi, Moeko, Yoshida, Sumiko, Noda, Takamasa, Sato, Noriko, Teraishi, Toshiya, Hattori, Kotaro et al. · 2018 · Journal of Affective Disorders
70. Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?
    Stephen M. Lawrie, Bayanne Olabi, Jérémy Hall, Andrew Mark McIntosh · 2011 · World Psychiatry
71. Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia
    George Foussias, Ishraq Siddiqui, Gagan Fervaha, Steve W. Mann, Krysta McDonald, Ofer Agid, Konstantine K. Zakzanis, Gary J. Remington · 2015 · Schizophrenia Research
72. Quality of life and cognitive dysfunction in people with schizophrenia
    Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Kyoko Taniguchi, Masahito Nakataki, Shusuke Numata, Shin’Ya Tayoshi, Ken Yamauchi, Satsuki Sumitani et al. · 2010 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
73. Happiness in first-episode schizophrenia
    Ofer Agid, Krysta McDonald, CYNTHIA O. SIU, Christopher Tsoutsoulas, Caroline Wass, Robert B. Zipursky, George Foussias, Gary J. Remington · 2012 · Schizophrenia Research
74. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia
    Mei San Ang, Nur Amirah Abdul Rashid, Max Lam, Attilio Rapisarda, Michael Kraus, Richard S.E. Keefe, Jimmy Lee · 2017 · Journal of Clinical Psychopharmacology
75. A Digit Symbol Coding Task as a Screening Instrument for Cognitive Impairment in First-Episode Psychosis
    César González‐Blanch, Rocío Pérez‐Iglesias, José Manuel Rodríguez-Sánchez, Gema Pardo‐García, Obdulia Martínez‐García, José Luis Vázquez‐Barquero, Benedicto Crespo‐Facorro · 2010 · Archives of Clinical Neuropsychology
76. Quality of life and its predictors in people with schizophrenia
    Masahito Tomotake · 2011 · The Journal of Medical Investigation
77. Effect of lifestyle coaching versus care coordination versus treatment as usual in people with severe mental illness and overweight: Two-years follow-up of the randomized CHANGE trial
    Ane Storch Jakobsen, Helene Speyer, Hans Christian Brix Nørgaard, Mette Karlsen, Merete Birk, Carsten Rygaard Hjorthøj, Ole N Mors, Jesper Krogh, Christian Nyfeldt Gluud, Charlotta Holm Pisinger et al. · 2017 · PLoS ONE
78. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments
    Arafat Hussein Al-Dujaili, Rana Fadhil Mousa, Hussein Kadhem Al‐Hakeim, Michael H. J. Maes · 2020 · Schizophrenia Bulletin
79. Clinical Recovery and Long-Term Association of Specialized Early Intervention Services vs Treatment as Usual Among Individuals With First-Episode Schizophrenia Spectrum Disorder: 20-Year Follow-up of the OPUS Trial
    Hansen, Helene Gjervig, Starzer, Marie, Nilsson, Sandra Feodor, Hjorthøj, Carsten, Albert, Nikolai, Nordentoft, Merete · 2023 · JAMA Psychiatry
80. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
    Chadia Haddad, Pascale Salameh, Hala Sacre, Jean‐Pierre Clément, Benjamin Calvet · 2023 · BMC Psychiatry
81. A comparison of insight into clinical symptoms versus insight into neuro-cognitive symptoms in schizophrenia.
    A. Medalia, J. Thysen · 2010 · Schizophrenia Research
82. A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia
    Joseph I. Friedman, David Mark Carpenter, Jing Lü, Fan Jin, Cheuk Ying Tang, LEONARD E. WHITE, Michael J. Parrella, Stephanie Bowler, Zeinab S. Elbaz, Lauren Flanagan et al. · 2008 · Journal of Clinical Psychopharmacology
83. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial
    Carsten Rygaard Hjorthøj, Allan Fohlmann, Anne‐Mette Larsen, Christian Nyfeldt Gluud, Mikkel Christoffer Berg B. Arendt, Merete Nordentoft · 2012 · Psychological Medicine
84. Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications
    Pu, Shenghong, Noda, Takamasa, Setoyama, Shiori, Nakagome, Kazuyuki · 2018 · Psychological Medicine
85. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
    Patricio O’Donnell, Cheng Dong, Venkatesha Murthy, Mahnaz Asgharnejad, Xiaoming Michael Du, Ann T. Summerfelt, Hong Lu, Lin Xu, Jens R. Wendland, Eduardo Dunayevich et al. · 2023 · Neuropsychopharmacology
86. Disconnected and underproductive speech in schizophrenia: Unique relationships across multiple indicators of social functioning
    Christopher R. Bowie, Maya Gupta, Katherine Holshausen · 2011 · Schizophrenia Research
87. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms.
    Vibeke Bliksted, Poul Videbech, Birgitte Fagerlund, Chris Frith · 2016 · Neuropsychology
88. Retinal layer abnormalities and their association with clinical and brain measures in psychotic disorders: A preliminary study
    Deepthi Bannai, Paulo L. Lizano, Megan A. Kasetty, Olivia Lutz, Victor Zeng, Suraj Sarvode, Leo A. Kim, Scot Kristian Hill, Carol A. Tamminga, Brett A. Clementz et al. · 2020 · Psychiatry Research Neuroimaging
89. Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment
    Marta Bosia, Andrea Zanoletti, Marco Spangaro, Mariachiara Buonocore, Margherita Bechi, Federica Cocchi, Adele Pirovano, Cristina Lorenzi, Placido Bramanti, Enrico Smeraldi et al. · 2014 · Psychiatry Research
90. A multimodal approach to investigate biomarkers for psychosis in a clinical setting: The integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project
    Shinsuke Koike, Yosuke Takano, Norichika Iwashiro, Yoshihiro Satomura, Motomu Suga, Tatsuya Nagai, Tatsunobu Natsubori, Mariko Tada, Yukika Nishimura, Syudo Yamasaki et al. · 2012 · Schizophrenia Research
91. The comprehension of idiomatic expressions in schizophrenic patients
    Antonio Schettino, Leonor J. Romero Lauro, F Crippa, Simona Anselmetti, Roberto Cavallaro, Costanza Papagno · 2009 · Neuropsychologia
92. The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia
    Thomas Quinlan, Scott C. Roesch, Eric L. Granholm · 2014 · Schizophrenia Research
93. Alteration of Gut Microbiome in Patients With Schizophrenia Indicates Links Between Bacterial Tyrosine Biosynthesis and Cognitive Dysfunction
    Florence Thirion, Helene Speyer, Tue H. Hansen, Trine Nielsen, Yong Fan, Emmanuelle Le Chatelier, Sébastien Fromentin, Magali Berland, Florian Plaza Oñate, Nicolas Pons et al. · 2022 · Biological Psychiatry Global Open Science
94. Lamotrigine for schizophrenia
    Titus Samson Premkumar, Jamie Pick · 2006 · Cochrane Database of Systematic Reviews
95. Psychosocial and neuropsychiatric predictors of subjective recovery from psychosis
    Anthony P. Morrison, Nick M. Shryane, Rosie Beck, Suzanne Heffernan, Heather Law, Monica McCusker, Richard P. Bentall · 2013 · Psychiatry Research
96. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders – Baseline and two-years findings from the CHANGE trial
    Ane Storch Jakobsen, Helene Speyer, Hans Christian Brix Nørgaard, Carsten Rygaard Hjorthøj, Jesper Krogh, Ole N Mors, Merete Nordentoft · 2018 · Schizophrenia Research
97. Using a Smartphone App to Identify Clinically Relevant Behavior Trends via Symptom Report, Cognition Scores, and Exercise Levels: A Case Series
    Hannah Wisniewski, Philip Henson, John Blake Torous · 2019 · Frontiers in Psychiatry
98. Life story chapters and narrative self-continuity in patients with schizophrenia
    Holm, Tine, Thomsen, Dorthe Kirkegaard, Bliksted, Vibeke · 2016 · Consciousness and Cognition
99. Disrupted modular organization of primary sensory brain areas in schizophrenia
    Cécile Bordier, Carlo Nicolini, Giulia Forcellini, Angelo Bifone · 2018 · NeuroImage Clinical
100. Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort
     Nikolaos Koutsouleris, Michelle Worthington, Dominic Dwyer, Lana Kambeitz‐Ilankovic, Rachele Sanfelici, Paolo Fusar‐Poli, Marlene Rosen, Stephan Ruhrmann, Alan Anticevic, Jean Addington et al. · 2021 · Biological Psychiatry